CHARACTERISTICS OF EPILEPSY IN CHILDREN WITH ANTI-N-METHYL-D-ASPARTATE RECEPTOR AUTOIMMUNE ENCEPHALITIS AT THE VIETNAM NATIONAL CHILDREN’S HOSPITAL
Main Article Content
Abstract
Objective: To describe the characteristics of epilepsy in children diagnosed with anti-N-methyl-D-aspartate receptor (NMDAR) autoimmune encephalitis (AE) at the Vietnam National Children’s Hospital. Subjects and Methods: A cross-sectional descriptive study, combining both retrospective and prospective data collection, was conducted on 35 pediatric patients with symptomatic epilepsy due to anti-NMDAR AE from January 2020 to May 2025. Results: The prevalence of symptomatic epilepsy in this cohort was 50%. The mean age was 7.7 ± 4 years, with a female-to-male ratio of 1:0.9. Seizures typically occurred approximately 3.1 ± 4.9 days after the onset of initial symptoms. Focal seizures were observed in 51.4% of cases, and generalized seizures in 48.6%, with a mean duration of 5 ± 3.7 minutes. At diagnosis, 80% of patients experienced ≤ 5 seizures per day. Electroencephalographic abnormalities were present in 58.1% of cases, primarily background slowing (77.8%), and epileptiform discharges in 27.8%. Brain magnetic resonance imaging revealed abnormalities in 34.4% of cases, most frequently involving the temporal lobes (45.4%) and frontoparietal regions (36.4%). Conclusion: Epilepsy is a common manifestation of anti-NMDAR AE in children. Accurate characterization of seizure features is essential for guiding antiepileptic therapy and prognosis.
Article Details
Keywords
Epilepsy, autoimmune encephalitis, NMDA receptor, children.
References
2. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17(2):117-123.
3. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521.
4. Bien CG, Holtkamp M. “Autoimmune epilepsy”: encephalitis with autoantibodies for epileptologists. Epilepsia. 2017;58(Suppl 2):50-59.
5. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti–NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
6. Chavez-Castillo M, Ruiz-Garcia M, Herrera-Mora P. Characterization and Outcomes of Epileptic Seizures in Mexican Pediatric Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Cureus. 2020;12(5):e8211.
7. Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurology Neuroimmunology & Neuroinflammation. 2020;7(2):e663
8. Liu X, Yan B, Wang R, et al. Clinical Characteristics and Follow-Up of Seizures in Children With Anti-NMDAR Encephalitis. Front Neurol. 2022;13:851360.
9. Gong Y, Zhang J, Liu M, et al. Seizure Semiology in Antibody-Associated Autoimmune Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1176.
10. Liu X, Yan B, Wang R, et al. Seizure Characteristics, Outcome, and Risk of Epilepsy in Pediatric Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Pediatr Neurol. 2020;105:35-40.